Silent Crohn’s disease may have little or no symptoms. It's important to monitor disease activity and treat the condition to ...
Crohn's disease belongs to a group of conditions known as inflammatory bowel diseases (IBD). This chronic condition causes ...
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
Sportschosun on MSN1d
A drop of blood distinguishes Crohn's disease from ulcerative colitis...Laying the foundation for customized treatment of inflammatory bowel diseaseInflammatory bowel disease (IBD) is expected to be more accurate and personalized. Recently, Professor Lee Hong-seop's team ...
A plant-based diet made up of mainly nutrient-dense plant foods, or an equally healthy omnivorous diet may help reduce the ...
The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).
Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an important role in the disease ...
In patients with Crohn's disease and intermediate to high preoperative corticosteroid use, primary ileocaecal resection leads ...
Tremfya is the first and only interleukin-23 inhibitor offering both subcutaneous and intravenous induction options for Crohn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback